资金流向方面，5月20日，尚荣医疗主力资金净流入654.95万元，近5日总体呈流出状态，5日共流出 14069.03万元。 深圳市尚荣医疗股份有限公司的主营业务是医疗产品生产销售、医疗服务、健康产业运营等。公司的主 要产品是医疗服务、医疗产品生产销售、健康产业运营。公司是国内最早将洁净技术引入医院手术部的 企业之一，公司的智能自控手术室产品荣获国家科技部、商务部、质量监督总局及环保总局颁发的国家 重点新产品荣誉，荣获深圳市人民政府颁发的科学技术进步二等奖，荣获深圳市科技和信息局颁发的高 新技术项目。公司是国家级高新技术企业、深圳市自主创新行业领军企业之一、深圳市高新技术企业、 深圳市知识产权优势企业。公司及子公司累计获得超过180项专利，成为公司持续发展的源动力。 5月20日，尚荣医疗今日收盘3.75元，下跌1.32%，滚动市盈率PE（当前股价与前四季度每股收益总和的 比值）达到141.78倍，总市值31.71亿元。 从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均49.51倍，行业中值36.17倍，尚荣医疗排 名第111位。 最新一期业绩显示，2025年一季报，公司实现营业收入2.80亿元，同比1.3 ...

Company Overview - Yancheng Port International Co., Ltd. primarily engages in trade, providing comprehensive logistics handling and related support services, as well as storage for petrochemical products [2] Financial Performance - As of December 31, 2024, Yancheng Port reported total revenue of 724 million yuan, a year-on-year decrease of 32.49% [1] - The net profit attributable to shareholders was -41.7551 million yuan, reflecting a year-on-year decline of 182.41% [1] - The gross profit margin stood at 0.98%, while the debt-to-asset ratio was 255.63% [1] Stock Performance - As of May 20, the stock price of Yancheng Port was 0.465 HKD per share, up 9.41% with a trading volume of 490,000 shares and a turnover of 227,300 HKD [1] - Over the past month, the stock has seen a cumulative decline of 13.27%, and a year-to-date decline of 1.16%, underperforming the Hang Seng Index by 16.31% [1] Industry Valuation - The average price-to-earnings (P/E) ratio for the industrial support sector is 14.85 times, with a median of 4.38 times [1] - Yancheng Port's P/E ratio is -12.14 times, ranking 32nd in the industry [1] - Other companies in the sector include Zhongbao New Materials (2.25 times), Changda Holdings (2.77 times), Shenglong Jinxiu International (4.12 times), Wancheng Group (4.38 times), and Shizishan Group (4.78 times) [1]

Company Overview - The company, Sichuan Portong Medical Equipment Group Co., Ltd., specializes in the research, design, manufacturing, integration, and operation services of medical gas equipment and systems, as well as medical clean equipment and systems [1] - The main products include medical gas equipment and systems, medical clean equipment and systems, medical devices, and other product sales and operation services [1] - The company has received multiple accolades, including "National Specialized and Innovative Small Giant Enterprise" and "National High-tech Enterprise" [1] Financial Performance - For Q1 2025, the company reported a revenue of 24.29 million yuan, a year-on-year decrease of 68.09% [1] - The net profit for the same period was 1.58 million yuan, reflecting a year-on-year decline of 85.25% [1] - The sales gross margin stood at 36.15% [1] Market Position - As of May 19, the company's stock closed at 19.42 yuan, with a rolling price-to-earnings (PE) ratio of 366.87, marking a new low in 29 days [1] - The average PE ratio for the medical device industry is 49.26, with a median of 36.71, positioning the company at 120th in the industry ranking [1][2] - The total market capitalization of the company is 1.942 billion yuan [1][2] Capital Flow - On May 19, the company experienced a net outflow of 796,600 yuan in principal funds, with a total outflow of 1.7702 million yuan over the past five days [1]

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Baoli International, indicating a significant decline in revenue and net profit in the latest quarterly report [1][2] - Baoli International's stock closed at 3.91 yuan, with a price increase of 2.89%, resulting in a rolling price-to-earnings (PE) ratio of 170.55 times, which is substantially higher than the industry average of 43.83 times [1][2] - The company's total market capitalization is reported at 3.603 billion yuan, ranking it 154th in the chemical products industry based on PE ratio [1][2] Group 2 - As of March 31, 2025, Baoli International had 40,212 shareholders, a decrease of 4,975 from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares per shareholder [1] - The main business activities of Baoli International include the production and sales of various types of modified asphalt products, as well as helicopter and aviation material sales, and investment in BT projects [1] - The latest quarterly report for Q1 2025 shows that the company achieved an operating revenue of 230 million yuan, a year-on-year decrease of 42.82%, and a net profit of 3.239 million yuan, down 26.61%, with a gross profit margin of 1.83% [1]

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Furuya Co., which operates in the medical device industry, specifically focusing on liver disease-related products and services [1][2] - As of May 19, Furuya Co. closed at 30.48 yuan, with a decline of 1.20%, resulting in a rolling price-to-earnings (PE) ratio of 81.84 times, significantly higher than the industry average of 49.26 times and the median of 36.71 times [1][2] - The total market capitalization of Furuya Co. is reported at 8.119 billion yuan, ranking it 102nd in the industry based on PE ratio [1][2] Group 2 - For the first quarter of 2025, Furuya Co. reported a revenue of 330 million yuan, reflecting a year-on-year increase of 2.35%, while the net profit was 28.637 million yuan, showing a decline of 32.97% compared to the previous year [1] - The gross profit margin for Furuya Co. stands at 76.76%, indicating a strong profitability despite the drop in net profit [1] - As of the first quarter of 2025, 18 institutions hold shares in Furuya Co., including 14 funds, 3 other entities, and 1 insurance company, with a total holding of 49.9011 million shares valued at 1.593 billion yuan [1]

Group 1 - The core viewpoint of the articles highlights Huamao Logistics' current market performance, including a stock price of 6.72 yuan, a decline of 3.45%, and a rolling PE ratio of 17.96 times, with a total market capitalization of 8.797 billion yuan [1] - The logistics industry has an average PE ratio of 24.56 times and a median of 24.03 times, positioning Huamao Logistics at the 27th rank within the industry [1] - As of the first quarter of 2025, seven institutions hold shares in Huamao Logistics, with a total holding of 658.1514 million shares valued at 3.745 billion yuan [1] Group 2 - Huamao Logistics specializes in third-party international comprehensive logistics and international logistics solutions, offering services such as comprehensive logistics, international air and sea freight, cross-border e-commerce logistics, special logistics, and third-party warehousing [1] - According to the latest rankings from the global logistics magazine "Transport Topics," Huamao Logistics ranks 16th among the top 50 global sea and air freight forwarders, indicating its competitive position in the international logistics market [1] - The latest financial results for the first quarter of 2025 show that the company achieved an operating revenue of 3.992 billion yuan, a year-on-year increase of 2.82%, and a net profit of 118 million yuan, a year-on-year decrease of 29.42%, with a gross profit margin of 11.39% [1]

风险提示：本文所提到的观点仅代表个人的意见，所涉及标的不作推荐，据此买卖，风险自负。 作者： 六亿居士 以下文章来源于六亿居士 ，作者六亿居士 六亿居士 . 雪球2024年度十大影响力用户。每周发布指数估值表，坚持指数基金(ETF)低估定投，分享指数基金基础 分析，让我们：买入有依，持有有底，卖出有据。 来源：雪球 在这一轮的年报数据更新后 ， 估值表内的红利指数 、 中证红利 、 红利低波 、 红利低波100等指 数的估值抬升明显 。 不少朋友都配有一定比例的红利 ， 对红利类指数的估值抬升关注度较高 。 今天我们就来聊一聊 ： 红利指数估值为何飙涨 ？ 先说因果 ： 估值表内红利类估值采用 中证指数官方数据 ， 这是因为红利类指数采用股息率加权 ， 其他第三方平台数据往往采用市值滚动市盈率(PETTM) ， 会有一定的误差 。 但是中证指数官方数据采用的是 " 静态市盈率 " (PE) ， 也就是在2025年4月30日之前 ， 各指数 采用2023年财报数据 ， 5月份后采用2024年财报数据 ， 致使近期出现估值的大幅变化 。 如果中证指数采用股息率加权的滚动市盈率(PETTM) ， 就没有这样一年一度 ...

智通财经5月16日电，宁波远洋(601022.SH)发布异动公告，根据中证指数网发布的数据，交通运输业、 仓储和邮政业中水上运输业2025年5月15日平均滚动市盈率为9.61倍，行业平均市净率为1.12倍，公司最 新滚动市盈率为25.89倍，最新市净率为2.44倍，明显高于同行业平均水平。敬请广大投资者注意二级市 场交易风险，理性决策，审慎投资。 宁波远洋：最新市净率明显高于同行业平均水平 ...

Group 1 - The core viewpoint of the articles highlights the performance and valuation of Yuexiu Capital, which has a current stock price of 6.51 yuan and a rolling PE ratio of 13.15 times, significantly lower than the industry average of 70.57 times [1][2] - Yuexiu Capital's total market capitalization stands at 32.662 billion yuan, ranking 7th in the diversified financial industry based on PE ratio [1][2] - As of the first quarter of 2025, 10 institutions hold shares in Yuexiu Capital, with a total holding of 397,502.52 thousand shares valued at 25.321 billion yuan [1] Group 2 - The main business of Yuexiu Capital includes non-performing asset management, financing leasing, private equity fund management, and capital investment services, with key products in non-performing asset management and new energy [1] - The latest financial results for the first quarter of 2025 show that the company achieved an operating income of 2.742 billion yuan, a year-on-year decrease of 9.42%, while net profit reached 657 million yuan, reflecting a year-on-year increase of 40.52% with a gross profit margin of 22.24% [1]

Core Viewpoint - David Medical's stock closed at 12.4 yuan, down 2.52%, with a rolling PE ratio of 85.59 times, and a total market value of 3.571 billion yuan [1] Company Summary - David Medical specializes in obstetric and pediatric care equipment, minimally invasive surgical instruments, and emergency ICU products, with key products including incubators, radiant warmers, jaundice treatment devices, EEG monitors, and more [1] - As of Q1 2025, two institutions held shares in David Medical, with a total of 1.2529 million shares valued at 0.015 billion yuan [1] - The company has received multiple honors, including recognition as a "Manufacturing Industry Single Champion Cultivation Enterprise" and "AAA Credit Rating Enterprise" [1] Industry Summary - The average PE ratio for the medical device industry is 49.46 times, with a median of 36.16 times, placing David Medical at 102nd in the industry ranking [2] - The company's Q1 2025 performance showed a revenue of 121 million yuan, a year-on-year decrease of 22.00%, and a net profit of 22.5677 million yuan, down 40.78%, with a gross margin of 57.13% [2]